When it comes to MS, there are many areas that are not yet met.
But there may be one area that stands out above all others: progressive MS. Despite the great progress we’ve made over the past two decades, we still don’t have truly effective therapies for primary or secondary progressive MS.
That is why we are so determined to address this area of unmet need.
In recent years, we have contributed to a global collaboration that is helping to accelerate research that will lead to effective drugs for progressive MS.
That collaboration is driven by ‘The Big Six’, powerful MS organizations that support and promote MS research, the National MS Society (US), the MS Society UK, the Canadian MS Society, the Italian and Danish MS Societies and MS Australia .
Working together as the International Progressive MS Alliance, and using research funds to add to ours, the Alliance has invested $43 million AUD to date, growing to $108 million by 2025.
With a strong commitment to integrating the voice of people with MS into everything they do, funding is being applied in three key areas:
- understand, prevent and reverse progression
- accelerate and improve clinical trials
- improve well-being.
A lot is happening, with the announcement this week that the Alliance is investing $5.5 million to support the next phase of a collaborative network led by Dr. Francisco Quintana, of Harvard Medical School, to further develop promising compounds targeting critical disease activities that drive progressive MS and brain injury.
The Alliance website provides more details on all funded projects – including work in Australia – and plans for the future.
All of this work is made possible by the donations to MS research made here and around the world. Without you this work would not be possible.